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Received 6 MBackground: Homeopathic Pathogenetic Trials (HPTs) are a pillar of homeopathy, a key
source of the symptoms characteristic of a particular homeopathic medicine. Homeo-
paths choose homeopathic medicines by comparing these remedy pictures with the
symptoms the patient is presenting. Thus, recognition of these symptom sets underpins
the clinical practice of homeopathy.
Objective: To test whether HPTs generate consistent and recognisable sets of symp-
toms in consecutive trials.
Design: Practising homeopaths, blinded to the homeopathicmedicine under investiga-
tion, were given the set of symptoms generated during an unpublishedHPT and asked to
identify the homeopathic medicine used.
Homeopathic trial substance: Ozone, prepared by homeopathic method to the ultra-
molecular dilution of 30c (1060 dilution), was chosen at random from twenty potential
medicines.
Results: Seven practising homeopaths were asked to make three guesses as to the
identity of the remedy. Initially from the full list of possible remedies (N = 2372). Two
of the seven homeopaths guessed the identity of the remedy correctly (p < 0.0001). Sub-
sequently, when their choice of possiblemedicineswas restricted to a list of 20, the same
two homeopaths selected the correct medicine, however none of the other practising
homeopaths did so (p = 0.2).
Discussion: The selection of the correct homeopathic medicine from the unrestricted
list (N = 2372 medicines) by two homeopaths is noteworthy given that the homeopathic
medicine used during the HPT was diluted well beyond Avogadro’s number and would
not be expected to produce any detectable or recognisable symptomatology. Possible
reasons why the remaining five homeopaths did not guess correctly are discussed.
Conclusion: The results show that practising homeopaths may be able to correctly
identify a homeopathic medicine from the set of symptoms generated during an HPT.
This suggests that such symptom pictures generated by taking an ultramolecular ho-
meopathic medicine are recognisable and specific to the substance taken. Since identi-ence: Jeremy Sherr, Dynamis School for Advanced Homoeopathic Studies, PO Box 652, Worcester WR5 3WN, UK.
r@dynamis.edu
ay 2012; revised 23 October 2013; accepted 8 December 2013
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109fication of the remedy was based on past HPT information held in the materia medica,
this demonstrates that HPT-generated symptom pictures are reproducible, thus vali-
dating the HPTmethodology. These promising preliminary findings warrant replication;
possible improvements to the trial design to be incorporated in future studieswere iden-
tified. Homeopathy (2014) 103, 108e112.
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A Homeopathic Pathogenetic Trial (HPT) (also known
as a “proving”) is a clinical study designed to explore the
possible clinical applications of a homeopathic medicine.
In an HPT, healthy participants take a substance prepared
according to the homeopathic pharmacopeia and record
any symptoms which develop within a specified time frame
after taking the dose; participants are blinded as to the iden-
tity of the substance. The set of symptoms generated during
an HPT is referred to as the ‘remedy picture’ or ‘symptom
picture’ of the particular homeopathic medicine being
tested. This information is subsequently collated into the
homeopathic materia medica. In the clinical setting, ho-
meopaths choose homeopathic medicines by comparing
these remedy pictures with the symptoms presented by
the patient. Since Hahnemann’s first proving, HPT infor-
mation has been entered, along with toxicology and clin-
ical data into homeopathic materia medica documents,
books and computer programs. In modern times, protocols
for administrating HPTs have been established, influencing
most trials conducted since 1994.1
The literature contains few published studies that have
explored the topic of HPTs. In 2000, Vickers et al. conduct-
ed an inter-rater reliability study.2 Using a database of 557
symptoms, including those recorded by placebo-takers,
two practitioners were instructed to indicate the symptoms
produced byMercurius solubilis. There was a moderate de-
gree of agreement (70%) between the two practitioners. In
2001, Vickers et al. studied the ability of homeopathic
practitioners to detect a homeopathic medicine experien-
tially.3 Participants, randomized and blinded, took either
a well-known homeopathic medicine (Bryonia alba) or a
placebo. Based on the symptoms they experienced, the par-
ticipants were to determine if they had taken verum or pla-
cebo. In this pilot study 60% of the homeopaths correctly
identified when they had taken the verum.
In 2004 Walach et al. performed an HPT of Cantharis
vesicatoria.4 The final symptoms collected during the trial
were rated by a homeopathic expert as typical or not of
Cantharis. The results showed that the symptoms produced
in the verum group were more typical of Cantharis
(p = 0.02) than placebo. In 2008 Walach et al. expanded
their 2004 study to test for specific and non-specific symp-
toms.5 Two HPTs were conducted in parallel: the first had
two arms (Ozone and placebo), the second study had three
arms (Ozone, Iridium and placebo). Using computerised
materia medica software, experts were asked to determine
which symptoms were typical (specific) or non-specific forthe homeopathic medicine tested. When combined, the re-
sults of the two studies indicated that the group taking
Ozone showed significantly more symptoms typical of
the remedy than the control group (p = 0.011).
In 2009 M€ollinger et al. performed an HPT with three
arms: two well-characterised homeopathic medicines (Na-
trum muriaticum 30C and Arsenicum 30C) and placebo.6
An expert was then asked to label each symptom generated
during the trial as typical of Natrum muriaticum, typical of
Arsenicum or non-specific. The results of the study showed
that healthy volunteers exhibit significantly more symp-
toms specific to the homeopathic medicine they had in-
gested compared to placebo (p < 0.001).
The same year, Piltan et al. published the results of their
HPT of Aconitum Napellus 30C using a cross-over double
blind randomised placebo-controlled trial design.7 An
expert was asked to determine the correct group allocation
of the volunteers based on the symptoms they reported. The
expert achieved a statistically significant success rate of
70.4% (p = 0.004).
A meaningful and relatively unexplored question is
whether multiple HPTs of the same homeopathic medicine
produce consistent sets of symptoms. Earlier studies identi-
fied issues with comparing symptom sets generated in
different trials. For instance, how does one equate a symp-
tom such as “head pain” with a modified symptom “head
pain, in the morning” or “head pain in the morning after
eating?” It is well-known amongst experienced HPT inves-
tigators that the retrials of homeopathicmedicines do not al-
ways produce identical symptoms, even in retrials with the
same participants.
Yet, in a clinical setting, homeopaths routinely and
effectively assess the similarity of non-identical symptom
sets (comparing those of the patients and the remedies).
The best explanation for how homeopaths accomplish
this is that the set of symptoms produced in HPTs create
a meaningful totality or pattern of symptoms that is suffi-
ciently characteristic as to be recognisable by a homeopath.
Therefore, to answer the question of whether multiple
HPTs of the same homeopathic medicine produce consis-
tent symptom pictures, a new approach was conceived
for the present study. Homeopathic practitioners would
be asked to identify a homeopathic medicine from the set
of symptoms it generated during an unpublished HPT. If
the practising homeopaths e a priori aware of the results
of previously published HPTs e are able to correctly iden-
tify the medicine, this would mean that symptom pictures
generated by different HPTs carry qualitatively similar in-
formation, characteristic of the medicine.Homeopathy
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HomeopMethods
Replication of previous HPT
The first HPT of Ozone was performed in 1993 by
Schadde and co-workers. The results were published in
19978 and the corresponding set of symptoms was then
added to the homeopathic literature and computerised ma-
teria medica. The present pilot study used the symptoms
drawn from a more recent HPTofOzone conducted byWa-
lach et al., the results of which were published in 2008.5
Unblinding of theWalach et al.HPTwas delayed until after
the present study was conducted, so as to preserve the
blinding required for the present study. The full list of
symptoms from the Walach et al. 2008 replication has
not yet been published, nor included in the materia medica.
A total of 53 participants took part in the replicated trial,
17 were novice volunteers from UK/Canada and 36 were
experienced volunteers from Freiburg, Germany. The
Ozone HPT replication was part of a blinded, randomised,
placebo-controlled parallel study of two previously tested
homeopathic medicines, Ozone and Iridium. 21 partici-
pants had Ozone (10 in the UK/Canada group, 11 in the
Freiburg group) while 20 participants had placebo (7 in
the UK/Canada group, 13 from the Freiburg group); the re-
maining 12 participants in the Freiburg group had Iridium
(not relevant to the present study). The UK/Canada group
contained student homeopaths naive to HPTs while the
Freiburg group had experienced participants. The set of
symptoms obtained for Ozone in the trial was made avail-
able before publication for use in the present pilot study.Homeopaths taking part in the study
The PI (JS) invited seven practising homeopaths, one
man and six women who had homeopathic experience
ranging from two to twenty years, to participate in this
study. All but one were known to the PI as well-
established teachers of homeopathy. They were chosen
based on their experience and reputation for expertise in
homeopathic materia medica and practice. The practising
homeopaths and the PI were blind to the name of the cor-
rect medicine. The name of the correct remedy for both
the Wallach et al. 2008 study and the present study were
revealed only after both studies had been completed.Medicine identification
The practising homeopaths were informed that the study
was based on a recent HPT of a previously trialled homeo-
pathic medicine. They were emailed the full set of 1439
symptoms from the HPT of Ozone conducted by Walach
et al.5 Symptoms from placebo-takers were included
within the data given to the practising homeopaths (20 par-
ticipants had placebo, 21 hadOzone) and the practising ho-
meopaths were informed of this fact. At this stage the trial
codes had not yet been revealed. Had the codes been un-
locked to remove the placebo symptoms, blinding of the
Walach et al. trial. would have been jeopardized.
Identification of the medicine by the practising homeo-
paths was undertaken in two steps. In the first phase theyathywere given an Excel sheet containing all 1439 symptoms
(including placebo symptoms), pre-sorted according to
their homeopathic classification (Mind, Dreams, Head,
Stomach etc). It is worth noting that the symptoms had
not been converted into materia medica symptoms or rep-
ertory rubrics and hence required a deeper level of interpre-
tation by the practising homeopaths. The practising
homeopaths were asked to study the symptoms and iden-
tify the most likely homeopathic medicine that could
have produced the set of symptoms. They were allowed
to use any tools they normally use in practice, i.e. books
and computerised materia medica and repertories. They
were instructed to make three choices from the unrestricted
total of homeopathic medicines known to date and listed in
the materia medica (N = 2372).9 In a second phase, having
handed in their answers, and having received no feedback
as to accuracy of their choices, the practising homeopaths
were then instructed to make another three attempts at
naming the medicine from a restricted list of twenty ho-
meopathic medicines.Selection of medicine
The twenty medicines on the restricted list were newly-
developed medicines that were fully represented in the ho-
meopathic literature. Table 1 depicts the restricted list of
the twenty medicines. The PI chose the initial list of twenty
homeopathic medicines but was blind to the one selected
for the trial. Ozone was randomly selected from these
twenty medicines by the pharmacist, who was the only per-
son in the study to know the medicine. The name of the
medicine was revealed only at the end of this study.Results
Unrestricted choice
When asked to select the homeopathic medicine from
the unrestricted list of all available homeopathic medicines
(N = 2372), two practising homeopaths were successful
(numbers 2 and 7, see Table 2) in identifying Ozone. The
probability of one individual choosing the correct homeo-
pathic medicine from the full list within three attempts is
p = 0.0013. The probability of two individuals selecting
the correct homeopathic medicine is calculated from the
binomial distribution to be p = 0.000033, which is statisti-
cally highly significant.Restricted choice
When asked to select the medicine from a restricted list
of twenty medicines, the same two practising homeopaths
(number 2 and 7, see Table 3), selected the correct medi-
cine. The probability of one homeopath choosing the cor-
rect answer from the restricted list within three attempts
is p = 0.16, which is not statistically significant. The prob-
ability of two homeopaths selecting the correct medicine
from the restricted list is p = 0.3, which is also not statisti-
cally significant. On the other hand the medicine Haliaee-
tus leucocephalus sanguinaria was selected four times
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nificant result (p = 0.01) discussed below.
Discussion
In this study, the correct homeopathic medicine was
identified far beyond the possibility of mere chance. Two
homeopaths succeeded in determining the correct medi-
cine out of the 2372 possible medicines, which is a statis-
tically highly significant result (p < 0.0001). This
demonstrates that HPTs generate specific and recognisable
sets of symptoms. If the symptoms generated by HPTs
were merely random placebo effects, identifying the cor-
rect medicine would not be possible as there would be no
pattern to recognise.
It is interesting to note that the homeopathic medicine,
Ozone 30c, used inWallach’s HPTwas diluted beyond Avo-
gadro’s numbere the point where theoretically nomolecule
of the original substance remains. Thismeans that the symp-
tom picture generated could not have been due to any mate-
rial effect of the Ozone, thus demonstrating a physiological
effect of ultramolecular homeopathic dilutions.
Given the complications inherent in the present study, it
is not entirely unexpected that five out of the seven prac-
tising homeopaths were unable to recognizeOzone. Firstly,
the set of symptoms given to homeopaths included not onlyTable 2 Choices for unrestricted list of medicines
Homeopath Choice Unrestricted list of medicines (N = 2373)
1 1 Natrum muriaticum





3 1 Haliaeetus leucocephalus sanguinaria
2
3
4 1 Germanium metallicum
2
3
5 1 Oncorhynchus tshawytscha
2 Haliaeetus leuocephalus sanguinaria
3





3symptoms from the Ozone group but also those coming
from the placebo group. Adding these random symptoms
made it harder to identify the correct medicine. Secondly,
Ozone is a relatively new addition to the homeopathic phar-
macopeia and so the homeopaths would be less familiar
with its symptom picture.
In the case of the restricted choice, we see that the most
often selected medicine was not the correct one,Ozone, but
Haliaeetus leucocephalus sanguinaria (American bald ea-
gle’s blood). This medicine was selected three times in the
unrestricted choices (highly significant, p < 0.0001) and
four times from the restricted list (p = 0.01). There is a
well-known overlap of themes in homeopathic medicines
developed from birds and from gases, which make them
seem superficially alike. The HPT databases of Ozone
andHaliaeetus leucocephalus sanguinaria share the theme
of “upward” or floating sensations, such as feeling light and
free, feelings of elation and euphoria and dreams of being
high up in the mountains.8,10 Several gas provings have
references to seeing or feeling like birds.9
Furthermore, the PI is well-known in the field for con-
ducting numerous HPTs of new substances, in particular
for his HPT of Haliaeetus leucocephalus sanguinaria in
1997.10 Awareness of the PI’s association with newly-
developed homeopathic medicines may have caused the
practising homeopaths to be somewhat predisposed to
choose a modern proving or one of the PI’s provings,
such as Haliaeetus leucocephalus sanguinaria. It is inter-
esting to note that only four out of the ten medicines chosen
by the practising homeopaths in the unrestricted choice
were classic polychrest homeopathic medicines already
known in the 19th century, possibly indicating that such a
bias occurred.
Let us consider further the hypothesis that the practising
homeopaths were biased towards a modern homeopathic
medicine due to the known involvement of the PI in mod-
ern HPTs. According to www.provings.com (a database of
provings in which the PI is involved), there were 600Table 3 Choices for restricted list of medicines
Homeopath Choice List of restricted medicines (N = 20)




2 Androctonus amoreuxii hebraeus
3
3 1 Bambusa arundinacea
2 Limenitis-bredowii
3 Lac-equinium
4 1 Haliaeetus leucocephalus sanguinaria
2 Androctonus amoreuxii hebraeus
3 Germanium metallicum
5 1 Oncorhynchus tshawytscha
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Homeopmodern HPTs registered at the time of the study. If we
restrict the number of possible medicines to this list of
600 modern HPTs, the p-value corresponding to this
configuration remains highly significant (p < 0.001).
Even when considering the case where the possible list of
medicines was only 150 of the modern medicines, the re-
sults would remain significant (p < 0.01).
Modern and older HPTs can be distinguished: modern
HPTs tend to generate more symptoms and more fully
developed symptoms, and the description of the symptoms
tends to use more modern language. This in principle
would allow a homeopath to differentiate between an old
and a new proving based on the number of symptoms
and language used in the descriptions. However, in this
case the practising homeopaths were aware that the data
originated from a modern repeat HPTof a known medicine
and would expect a large number of symptoms with mod-
ern descriptions. They would therefore not be able to infer
anything about the medicine from this information.
The mix of experienced and inexperienced HPT volun-
teers in the replicated HPT may have increased the chal-
lenge for the practising homeopaths trying to identify the
medicine. Experienced HPT participants generate shorter
lists of symptoms and are more specific in their descrip-
tions.5 Experienced HPT volunteers are more aware of
their reactions and better able to discern newly-appeared,
and sometimes subtle symptoms, from pre-existing ones.
With the inclusion of inexperienced provers, some less-
specific symptoms were added to the list rendering the
task of the practising homeopaths more difficult.
The results of the present study support the conclusions
of the Walach et al. 2004, 2008 and the Mollinger et al.
2009 studies, which showed that symptoms typical of the
homeopathic medicine occur more frequently when volun-
teers take verum than placebo.4e6 It would be interesting to
replicate the present study using more commonly known
and classically proved medicines, as well as experienced
HPT participants. Using a larger number of experienced
homeopaths to judge the symptoms would improve the
significance of the results. We also recommend removing
placebo symptoms from the final HPT data.
Conclusions
In this study, some practising homeopaths were able to
correctly identify an ultramolecular homeopathic medicine
from the symptoms it generated when taken by healthy vol-
unteers during an HPT. Two homeopaths out of seven taking
part in the study correctly guessed the remedy,Ozone, out of
the N = 2372 remedies in the materia medica. This highly
significant result (p<0.0001) supports the hypothesis that ul-
tramolecular homeopathic dilutions are not ‘simply water’.
Further, this study demonstrates that symptoms gener-
ated by taking an ultramolecular homeopathic medicine
are recognisable and specific to the substance taken, unlike
the random symptoms generated by a placebo. Also, since
identification of the remedy was based on past HPT infor-
mation held in the materia medica, this demonstrates that
HPT-generated symptom pictures are reproducible.athyEach homeopathic medicine has an associated symptom
picture generated primarily through HPTs. In the clinical
setting, homeopaths prescribe by selecting the homeopath-
ic medicine with the symptom picture most similar to that
of the symptoms presented by the patient.
The homeopathic prescribing process therefore hinges
on two factors: the generation of consistent symptom pic-
tures by HPTs and the ability of homeopaths to correctly
recognise those symptom pictures. This study tends to vali-
date both these aspects of homeopathic practice.Conflictof intereststatement
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